Omalizumab facilitates rapid oral desensitization for peanut allergy

AJ MacGinnitie, R Rachid, H Gragg, SV Little… - Journal of Allergy and …, 2017 - Elsevier
Background Peanut oral immunotherapy is a promising approach to peanut allergy, but
reactions are frequent, and some patients cannot be desensitized. The anti-IgE medication
omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut
updosing and decrease reactions. Objective We sought to evaluate whether omalizumab
facilitated rapid peanut desensitization in highly allergic patients. Methods Thirty-seven
subjects were randomized to omalizumab (n= 29) or placebo (n= 8). After 12 weeks of …